Sign inJoin waitlistJoin the waitlist

Musa Yilmaz

Associate Professor, Leukemia · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
Baylor College of Medicine
2013–2016
University of Texas M D Anderson Cancer Center
2012–2013
The University of Texas Medical School
2009–2012
Doctor of Medicine
2004–2008

Research

Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · 426 citations
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Nature Medicine · 2023 · 334 citations
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · 294 citations

Hagop Kantarjian
124 papers
Tapan Kadia
115 papers
Nicholas Short
114 papers · 4 as a fellow
Elias Jabbour
106 papers
Naval Daver
106 papers
Courtney DiNardo
102 papers
GB
Gautam Borthakur
93 papers
Guillermo Garcia-Manero
82 papers
Marina Konopleva
74 papers
Ghayas Issa
71 papers
KS
Koji Sasaki
66 papers · 2 as a fellow
Naveen Pemmaraju
61 papers

Clinical trials

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2020–2027
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2019–2027
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2018–2028